A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia

John M. Kane, Olawale Osuntokun, Ludmila A. Kryzhanovskaya, Wen Xu, Virginia L. Stauffer, Susan B. Watson, Alan Breier

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Objective: To evaluate the effectiveness of olanzapine versus aripiprazole in patients with schizophrenia. Method: Patients aged 18 to 65 years with schizophrenia (diagnosed according to DSM-IV-TR criteria) were randomly assigned to either olanzapine (n = 281) or aripiprazole (n = 285) for 28 weeks of double-blind treatment. The primary outcome was time to all-cause discontinuation. Efficacy was measured by Positive and Negative Syndrome Scale (PANSS) total change from baseline. Time-to-event data were analyzed via the Kaplan-Meier method. The study was conducted from October 2003 to July 2007. Results: Treatment groups did not differ significantly in time to all-cause discontinuation (p = .067) or all-cause discontinuation rate (olanzapine, 42.7% vs. aripiprazole, 50.2%; p = .053). Olanzapine-treated patients had significantly longer time to efficacy-related discontinuation (p < .001) and a significantly lower efficacy-related discontinuation rate (olanzapine, 8.9% vs. aripiprazole, 16.8%; p = .006). Olanzapine-treated patients had a significantly greater mean decrease (last observation carried forward) in PANSS total score (-30.2) than did aripiprazole-treated patients (-25.9, p = .014). Olanzapine-treated patients had a mean weight change of +3.4 kg (vs. +0.3 kg for aripiprazole-treated patients; p < .001) and a significantly greater incidence of ≥ 7% body weight gain at any time (40.3% vs. 16.4%; p < .001). Fasting mean glucose change was +4.87 mg/dL for olanzapine and +0.90 mg/dL for aripiprazole (p = .045). Incidence of baseline glucose < 100 mg/dL and ≥ 126 mg/dL at any time was 1.7% for olanzapine and 0.6% for aripiprazole (p = .623). Fasting mean total cholesterol change was +4.09 mg/dL for olanzapine and -9.85 mg/dL for aripiprazole (p < .001). Incidence of baseline total cholesterol < 200 mg/dL and ≥ 240 mg/dL at any time was 9.2% for olanzapine and 1.5% for aripiprazole (p = .008). Fasting mean triglycerides change was +25.66 mg/dL for olanzapine and -17.52 mg/dL for aripiprazole (p < .001). Treatment groups did not significantly differ on measures of extrapyramidal symptoms. Conclusion: Treatment groups did not differ significantly on the primary outcome. Olanzapine-treated patients had significantly greater improvement in symptom efficacy at 28 weeks as well as significantly greater mean increases in weight and glucose and significantly greater worsening on lipids parameters. Trial Registration: clinicaltrials.gov Identifier: NCT00088049.

Original languageEnglish
Pages (from-to)572-581
Number of pages10
JournalJournal of Clinical Psychiatry
Volume70
Issue number4
DOIs
StatePublished - Apr 2009

Fingerprint

olanzapine
Double-Blind Method
Schizophrenia
Therapeutics
Fasting
Glucose
Aripiprazole
Incidence
Cholesterol

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. / Kane, John M.; Osuntokun, Olawale; Kryzhanovskaya, Ludmila A.; Xu, Wen; Stauffer, Virginia L.; Watson, Susan B.; Breier, Alan.

In: Journal of Clinical Psychiatry, Vol. 70, No. 4, 04.2009, p. 572-581.

Research output: Contribution to journalArticle

Kane, John M. ; Osuntokun, Olawale ; Kryzhanovskaya, Ludmila A. ; Xu, Wen ; Stauffer, Virginia L. ; Watson, Susan B. ; Breier, Alan. / A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. In: Journal of Clinical Psychiatry. 2009 ; Vol. 70, No. 4. pp. 572-581.
@article{cd612b07c7864c6c925e26256da50120,
title = "A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia",
abstract = "Objective: To evaluate the effectiveness of olanzapine versus aripiprazole in patients with schizophrenia. Method: Patients aged 18 to 65 years with schizophrenia (diagnosed according to DSM-IV-TR criteria) were randomly assigned to either olanzapine (n = 281) or aripiprazole (n = 285) for 28 weeks of double-blind treatment. The primary outcome was time to all-cause discontinuation. Efficacy was measured by Positive and Negative Syndrome Scale (PANSS) total change from baseline. Time-to-event data were analyzed via the Kaplan-Meier method. The study was conducted from October 2003 to July 2007. Results: Treatment groups did not differ significantly in time to all-cause discontinuation (p = .067) or all-cause discontinuation rate (olanzapine, 42.7{\%} vs. aripiprazole, 50.2{\%}; p = .053). Olanzapine-treated patients had significantly longer time to efficacy-related discontinuation (p < .001) and a significantly lower efficacy-related discontinuation rate (olanzapine, 8.9{\%} vs. aripiprazole, 16.8{\%}; p = .006). Olanzapine-treated patients had a significantly greater mean decrease (last observation carried forward) in PANSS total score (-30.2) than did aripiprazole-treated patients (-25.9, p = .014). Olanzapine-treated patients had a mean weight change of +3.4 kg (vs. +0.3 kg for aripiprazole-treated patients; p < .001) and a significantly greater incidence of ≥ 7{\%} body weight gain at any time (40.3{\%} vs. 16.4{\%}; p < .001). Fasting mean glucose change was +4.87 mg/dL for olanzapine and +0.90 mg/dL for aripiprazole (p = .045). Incidence of baseline glucose < 100 mg/dL and ≥ 126 mg/dL at any time was 1.7{\%} for olanzapine and 0.6{\%} for aripiprazole (p = .623). Fasting mean total cholesterol change was +4.09 mg/dL for olanzapine and -9.85 mg/dL for aripiprazole (p < .001). Incidence of baseline total cholesterol < 200 mg/dL and ≥ 240 mg/dL at any time was 9.2{\%} for olanzapine and 1.5{\%} for aripiprazole (p = .008). Fasting mean triglycerides change was +25.66 mg/dL for olanzapine and -17.52 mg/dL for aripiprazole (p < .001). Treatment groups did not significantly differ on measures of extrapyramidal symptoms. Conclusion: Treatment groups did not differ significantly on the primary outcome. Olanzapine-treated patients had significantly greater improvement in symptom efficacy at 28 weeks as well as significantly greater mean increases in weight and glucose and significantly greater worsening on lipids parameters. Trial Registration: clinicaltrials.gov Identifier: NCT00088049.",
author = "Kane, {John M.} and Olawale Osuntokun and Kryzhanovskaya, {Ludmila A.} and Wen Xu and Stauffer, {Virginia L.} and Watson, {Susan B.} and Alan Breier",
year = "2009",
month = "4",
doi = "10.4088/JCP.08m04421",
language = "English",
volume = "70",
pages = "572--581",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "4",

}

TY - JOUR

T1 - A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia

AU - Kane, John M.

AU - Osuntokun, Olawale

AU - Kryzhanovskaya, Ludmila A.

AU - Xu, Wen

AU - Stauffer, Virginia L.

AU - Watson, Susan B.

AU - Breier, Alan

PY - 2009/4

Y1 - 2009/4

N2 - Objective: To evaluate the effectiveness of olanzapine versus aripiprazole in patients with schizophrenia. Method: Patients aged 18 to 65 years with schizophrenia (diagnosed according to DSM-IV-TR criteria) were randomly assigned to either olanzapine (n = 281) or aripiprazole (n = 285) for 28 weeks of double-blind treatment. The primary outcome was time to all-cause discontinuation. Efficacy was measured by Positive and Negative Syndrome Scale (PANSS) total change from baseline. Time-to-event data were analyzed via the Kaplan-Meier method. The study was conducted from October 2003 to July 2007. Results: Treatment groups did not differ significantly in time to all-cause discontinuation (p = .067) or all-cause discontinuation rate (olanzapine, 42.7% vs. aripiprazole, 50.2%; p = .053). Olanzapine-treated patients had significantly longer time to efficacy-related discontinuation (p < .001) and a significantly lower efficacy-related discontinuation rate (olanzapine, 8.9% vs. aripiprazole, 16.8%; p = .006). Olanzapine-treated patients had a significantly greater mean decrease (last observation carried forward) in PANSS total score (-30.2) than did aripiprazole-treated patients (-25.9, p = .014). Olanzapine-treated patients had a mean weight change of +3.4 kg (vs. +0.3 kg for aripiprazole-treated patients; p < .001) and a significantly greater incidence of ≥ 7% body weight gain at any time (40.3% vs. 16.4%; p < .001). Fasting mean glucose change was +4.87 mg/dL for olanzapine and +0.90 mg/dL for aripiprazole (p = .045). Incidence of baseline glucose < 100 mg/dL and ≥ 126 mg/dL at any time was 1.7% for olanzapine and 0.6% for aripiprazole (p = .623). Fasting mean total cholesterol change was +4.09 mg/dL for olanzapine and -9.85 mg/dL for aripiprazole (p < .001). Incidence of baseline total cholesterol < 200 mg/dL and ≥ 240 mg/dL at any time was 9.2% for olanzapine and 1.5% for aripiprazole (p = .008). Fasting mean triglycerides change was +25.66 mg/dL for olanzapine and -17.52 mg/dL for aripiprazole (p < .001). Treatment groups did not significantly differ on measures of extrapyramidal symptoms. Conclusion: Treatment groups did not differ significantly on the primary outcome. Olanzapine-treated patients had significantly greater improvement in symptom efficacy at 28 weeks as well as significantly greater mean increases in weight and glucose and significantly greater worsening on lipids parameters. Trial Registration: clinicaltrials.gov Identifier: NCT00088049.

AB - Objective: To evaluate the effectiveness of olanzapine versus aripiprazole in patients with schizophrenia. Method: Patients aged 18 to 65 years with schizophrenia (diagnosed according to DSM-IV-TR criteria) were randomly assigned to either olanzapine (n = 281) or aripiprazole (n = 285) for 28 weeks of double-blind treatment. The primary outcome was time to all-cause discontinuation. Efficacy was measured by Positive and Negative Syndrome Scale (PANSS) total change from baseline. Time-to-event data were analyzed via the Kaplan-Meier method. The study was conducted from October 2003 to July 2007. Results: Treatment groups did not differ significantly in time to all-cause discontinuation (p = .067) or all-cause discontinuation rate (olanzapine, 42.7% vs. aripiprazole, 50.2%; p = .053). Olanzapine-treated patients had significantly longer time to efficacy-related discontinuation (p < .001) and a significantly lower efficacy-related discontinuation rate (olanzapine, 8.9% vs. aripiprazole, 16.8%; p = .006). Olanzapine-treated patients had a significantly greater mean decrease (last observation carried forward) in PANSS total score (-30.2) than did aripiprazole-treated patients (-25.9, p = .014). Olanzapine-treated patients had a mean weight change of +3.4 kg (vs. +0.3 kg for aripiprazole-treated patients; p < .001) and a significantly greater incidence of ≥ 7% body weight gain at any time (40.3% vs. 16.4%; p < .001). Fasting mean glucose change was +4.87 mg/dL for olanzapine and +0.90 mg/dL for aripiprazole (p = .045). Incidence of baseline glucose < 100 mg/dL and ≥ 126 mg/dL at any time was 1.7% for olanzapine and 0.6% for aripiprazole (p = .623). Fasting mean total cholesterol change was +4.09 mg/dL for olanzapine and -9.85 mg/dL for aripiprazole (p < .001). Incidence of baseline total cholesterol < 200 mg/dL and ≥ 240 mg/dL at any time was 9.2% for olanzapine and 1.5% for aripiprazole (p = .008). Fasting mean triglycerides change was +25.66 mg/dL for olanzapine and -17.52 mg/dL for aripiprazole (p < .001). Treatment groups did not significantly differ on measures of extrapyramidal symptoms. Conclusion: Treatment groups did not differ significantly on the primary outcome. Olanzapine-treated patients had significantly greater improvement in symptom efficacy at 28 weeks as well as significantly greater mean increases in weight and glucose and significantly greater worsening on lipids parameters. Trial Registration: clinicaltrials.gov Identifier: NCT00088049.

UR - http://www.scopus.com/inward/record.url?scp=65449123582&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65449123582&partnerID=8YFLogxK

U2 - 10.4088/JCP.08m04421

DO - 10.4088/JCP.08m04421

M3 - Article

C2 - 19323965

AN - SCOPUS:65449123582

VL - 70

SP - 572

EP - 581

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 4

ER -